Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.

PloS one - 1 Jan 2016

Mori Hitomi, Kubo Makoto, Nishimura Reiki, Osako Tomofumi, Arima Nobuyuki, Okumura Yasuhiro, Okido Masayuki, Yamada Mai, Kai Masaya, Kishimoto Junji, Miyazaki Tetsuyuki, Oda Yoshinao, Otsuka Takao, Nakamura Masafumi

Abstract excerpt

BACKGROUND: Triple-negative breast cancer (TNBC) is a heterogeneous tumor that encompasses many different subclasses of the disease. In this study, we assessed BRCAness, defined as the shared characteristics between sporadic and BRCA1-mutated tumors, in a large cohort of TNBC cases. METHODS: The BRCAness of 262 patients with primary TNBCs resected between January 2004 and December 2014 was determined through the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Anthracyclines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibiotics, Antineoplastic

Share to Biomarkers

Share to Chemotherapy, Adjuvant

Share to Genes, BRCA1

Share to Treatment Outcome

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 27977696
DOI: 10.1371/journal.pone.0167016
PMCID: PMC5158199

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.PMID 27977696Read ↗

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.Semantic proximity Read ↗

BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.Semantic proximity Read ↗

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriersSemantic proximity Read ↗

BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations.Semantic proximity Read ↗

Triple-negative breast cancer and the need for new therapeutic targets.Semantic proximity Read ↗

Triple Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant ChemotherapySemantic proximity Read ↗

Biology and Management of Patients With Triple-Negative Breast CancerSemantic proximity Read ↗

Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancersSemantic proximity Read ↗

Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast CancerSemantic proximity Read ↗

Therapeutic Advances and New Directions for Triple-Negative Breast CancerSemantic proximity Read ↗

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic AnalysisSemantic proximity Read ↗

Clinicopathological and Molecular Study of Triple-Negative Breast Cancer in Algerian Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.